Webster Stephen W 4

What Happened

• Stephen W. Webster, a director of Cullinan Therapeutics (CGEM), was granted a derivative award on 2026-06-16 covering 25,319 shares. The filing reports an acquisition at $0.00 (no cash paid) — this is a grant/award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Transaction type: Award/Grant of a derivative (reported as "A"); reported acquisition price $0.00.
• Shares/units involved: 25,319 (represents a right to purchase 25,319 shares).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The award vests in full on the earlier of (i) June 16, 2027 or (ii) the date of the issuer’s next annual meeting, subject to Webster’s continued service as a director on the vesting date.

Context

• This is a deferred/conditional equity grant (a derivative right), not an immediate purchase or sale. It does not indicate any immediate cash outlay, exercise, or sale of shares; vesting conditions must be met before Webster obtains the underlying shares. Grants like this are commonly used for director compensation and do not, by themselves, imply a buy or sell signal.